Pierre Fabre Taps XtalPi’s AI and Robotics Platform for Oncology Drug Discovery Collaboration
Key Points
- Pierre Fabre and XtalPi will collaborate to identify novel small-molecule candidates, initially for oncology with potential expansion to dermatology and rare diseases.
- XtalPi will apply AI and robotics for drug design while Pierre Fabre leads candidate selection and clinical and commercial development.
- The agreement includes upfront and milestone payments plus downstream participation; the value was not disclosed.
Laboratoires Pierre Fabre has entered into a research collaboration with XtalPi Holdings Limited to identify and develop novel small-molecule drug candidates, initially targeting oncology indications, with the potential to expand the partnership into dermatology and rare diseases.
Under the agreement, XtalPi will apply its artificial intelligence (AI) capabilities and robotics platform to design new small-molecule therapeutics against a series of undisclosed biological targets. Pierre Fabre will contribute its expertise in disease biology, drug discovery, translational research and clinical development, taking responsibility for selecting promising candidates and advancing them through subsequent clinical and commercial development.
The collaboration will focus on targets that have historically presented challenges for drug discovery, including those considered difficult to address with conventional approaches. By combining computational drug design and automated research capabilities with established pharmaceutical development expertise, the companies aim to improve the identification of potential clinical candidates across multiple research programs.
For Pierre Fabre, the partnership adds an AI-driven discovery component to its research and development strategy and broadens its capabilities in identifying new therapeutic opportunities. For XtalPi, the agreement represents another application of its integrated AI and robotics technologies in early-stage pharmaceutical research.
Financial terms include an upfront payment, milestone payments tied to development progress and additional downstream economic participation. The companies did not disclose the specific value of the agreement.
Visit https://www.pierre-fabre.com/fr for more information.
Total Page Views: 5
